The estimated Net Worth of Kenneth J Gorelick is at least $28.5 Thousand dollars as of 23 November 2016. Kenneth Gorelick owns over 5,000 units of NextTrip stock worth over $28,500 and over the last 8 years he sold NTRP stock worth over $0. In addition, he makes $0 as Director at NextTrip.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Kenneth Gorelick NTRP stock SEC Form 4 insiders trading
Kenneth has made over 2 trades of the NextTrip stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of NTRP stock worth $1,450 on 23 November 2016.
The largest trade he's ever made was buying 5,000 units of NextTrip stock on 23 November 2016 worth over $1,450. On average, Kenneth trades about 2,000 units every 18 days since 2016. As of 23 November 2016 he still owns at least 10,000 units of NextTrip stock.
You can see the complete history of Kenneth Gorelick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Gorelick biography
Dr. Kenneth J. Gorelick is Director of the Company. Dr. Gorelick is the Managing Director of Zymo Consulting Group LLC, that provides consulting services to the biopharmaceutical industry, specializing in clinical development and regulatory affairs. He currently serves as Chair of the Program Advisory Board for Asahi Kasei Pharma America and as Chief Medical Officer for PIN Pharma, among others. Dr. Gorelick received his MD from Cornell University, and post-doctoral training at St. Louis University and Stanford University where he was also a member of the clinical faculty. Previously he was Vice President of Global Clinical Research and Development at DuPont Merck Pharmaceutical Company.
What's Kenneth Gorelick's mailing address?
Kenneth's mailing address filed with the SEC is 50 PARK PLACE, SUITE 1401, , NEWARK, NJ, 07102.
Insiders trading at NextTrip
Over the last 10 years, insiders at NextTrip have traded over $2,644 worth of NextTrip stock and bought 245,000 units worth $210,900 . The most active insiders traders include Bruce Bernstein, Ivan P. Gergel, and Andrew D Perlman. On average, NextTrip executives and independent directors trade stock every 180 days with the average trade being worth of $69,913. The most recent stock trade was executed by Jonathan Schechter on 30 October 2020, trading 25,000 units of NTRP stock currently worth $24,500.
What does NextTrip do?
sigma labs, inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3d printing, and other advanced manufacturing technologies. sigma labs is pioneering the commercialization of in-process metallurgical and geometric quality assurance monitoring technology. printrite3d® with its software modules inspect™, contour™ and analytics™ is the industry's first, commercially available, platform independent, third party in-process quality monitoring system for metal additive manufacturing. it is available as a fully embedded oem installation or a stand-alone connection to your existing machines. additionally, sigma labs conducts contract metal 3d printing in materials inconnel718, 316 stainless, titanium, aluminum and ms1 tool steel. for more information please visit www.sigmalabsinc.com. for inquiries contact: sales@sigmalabsinc.com follow sigma labs on twi
What does NextTrip's logo look like?
Complete history of Kenneth Gorelick stock trades at NextTrip
NextTrip executives and stock owners
NextTrip executives and other stock owners filed with the SEC include:
-
Robert Weinstein,
Chief Financial Officer, Executive Vice President -
Jonathan Schechter,
Director -
Kenneth Gorelick,
Director -
Ivan Gergel,
Director -
Bruce Bernstein,
Director -
Paula Trzepacz,
Executive Vice President and Chief Medical Officer -
William Singer,
Vice Chairman of the Board -
Charles Ryan,
Chief Executive Officer, Director -
Daniel Alkon,
President, Chief Scientific Officer -
Joshua Silverman,
Chairman of the Board -
Shana Phares,
Director -
George Perry,
Director -
Michael Ciraolo,
COO and General Counsel -
Susanne Wilke,
Director -
James Gottlieb,
Director -
Andrew D Perlman,
Director -
Warren W Wasiewski,
-
Paul E. Freiman,
See Remarks -
Charles S Ramat,
President and CEO -
Larry Douglas Altstiel,
Director -
Jay M Haft,
Director -
John H Abeles,
10% owner -
David Crockford,